A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

Alcon Research

Overview

The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Open-Angle Glaucoma Ocular Hypertension

Interventions

Brimonidine Tartrate Ophthalmic SolutionDRUG

Eligibility

Sex: ALLMin age: 2 Months

Medical Language ↔ Plain English

* Patients of any race * two (2) years of age or older * of either sex * diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component)or ocular hypertension

Locations (1)

Alcon Call Center

Fort Worth, Texas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.